Skip to main content
Cardiogeni Plc logo

Cardiogeni Plc — Investor Relations & Filings

ISIN · GB00BTBLFC12 LEI · 9845000F8F59ATZD8F92 Aquis Stock Exchange Manufacturing
Open in API
Filings indexed 24 across all filing types
Latest filing 2026-05-26 Capital/Financing Update
Country GB United Kingdom
Listing Aquis Stock Exchange

About Cardiogeni Plc

https://cardiogeni.com/

Cardiogeni Plc is a clinical-stage biotechnology company specializing in the development of regenerative medicines for the treatment of heart failure. Founded by Nobel Laureate Sir Martin Evans, the company focuses on creating novel therapies to address life-threatening cardiovascular diseases. Cardiogeni aims to become a market leader in heart failure regeneration by advancing its product pipeline, which includes candidates like heartcel, through clinical development and commercialization.

Recent filings

Filing Released Lang Actions
Repayment of Convertible Loan Notes
Capital/Financing Update Classification · 85% confidence The document is an RNS news release from Cardiogeni PLC announcing the full repayment of its Convertible Loan Notes (£810,000). This is an update on the company’s financing activities and a change in capital structure. It is not a financial report, dividend notice, or management change, but a capital/financing update.
2026-05-26 English
Update on Share Exchange Agreement
Capital/Financing Update Classification · 85% confidence The document is a short RNS announcement (under 5,000 characters) reporting the receipt of loan funding and completion of a Share Exchange Agreement. It is clearly an update on the company's fundraising and capital structure changes, which falls under the Capital/Financing Update category (CAP).
2026-04-29 English
TR-1: Standard notification of major holdings
Major Shareholding Notification Classification · 95% confidence The document is a TR-1 Standard Form for Notification of Major Holdings under the FCA/DTR rules, detailing shareholding percentages, threshold crossing date, and voting rights. This clearly corresponds to a major shareholding notification. According to the taxonomy, this maps to Major Shareholding Notification (Code: MRQ).
2026-04-27 English
Completion Share Exchange Agreement Issue Equity
Share Issue/Capital Change Classification · 90% confidence The document is an RNS announcement reporting the completion of a Share Exchange Agreement and detailed issuance of new ordinary shares to directors, advisers, and ASA holders, plus application for Admission to trading and Total Voting Rights. This constitutes a change in the company’s share capital and issuance of equity. There is no full financial report, earnings release, or management discussion, and it is not a takeover or legal notice. Therefore it falls under Share Issue/Capital Change.
2026-04-21 English
Update on Share Exchange Agreement with Kira
M&A Activity Classification · 85% confidence The document is an RNS announcement titled “Update on Share Exchange Agreement with Kira Health Invest AG.” It provides an update on a share exchange transaction, which is a form of corporate merger or acquisition activity. It is not a full report or financials, nor an earnings release or management change notice. Therefore it falls under M&A Activity (Code: TAR).
2026-04-13 English
Update on Share Exchange Agreement with Kira
M&A Activity Classification · 82% confidence The document is an RNS announcement providing an update on the status of a Share Exchange Agreement (effectively an M&A transaction) between Cardiogeni PLC and Kira Health Invest AG. It is not simply a regulatory filing about a report release, nor a routine capital issuance; rather it details progress towards completion of a merger-like share exchange. This aligns with M&A Activity (Code: TAR).
2026-04-01 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.